HLVXHilleVax, Inc.

Nasdaq hillevax.com


$ 1.74 $ 0.00 (0 %)    

Friday, 06-Sep-2024 15:59:36 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 1.74
$ 1.74 x 500
-- x --
-- - --
$ 1.55 - $ 20.22
218,336
na
86.63M
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-20-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-17-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 06-08-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-hillevax-maintains-2-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates HilleVax (NASDAQ:HLVX) with a Neutral and maintains $2 price tar...

 hillevax-q2-2024-gaap-eps-083-misses-043-estimate

HilleVax (NASDAQ:HLVX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.43) by...

 hillevax-plans-reduction-of-approximately-41-employees-or-40-of-its-workforce

The reduction of approximately 41 employees, or approximately 40% of the company's workforce, is intended to preserve cash ...

 leerink-partners-downgrades-hillevax-to-market-perform-lowers-price-target-to-2

Leerink Partners analyst David Risinger downgrades HilleVax (NASDAQ:HLVX) from Outperform to Market Perform and lowers the p...

 stifel-downgrades-hillevax-to-hold-lowers-price-target-to-3

Stifel analyst Stephen Willey downgrades HilleVax (NASDAQ:HLVX) from Buy to Hold and lowers the price target from $34 to $3.

 hc-wainwright--co-downgrades-hillevax-to-neutral

HC Wainwright & Co. analyst Matthew Caufield downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.

 stocks-hold-steady-small-caps-rise-french-equities-slip-after-surprise-win-by-left-wing-bloc-whats-driving-markets-monday

U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by mid...

 guggenheim-downgrades-hillevax-to-neutral

Guggenheim analyst Seamus Fernandez downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.

 vaccine-developer-hillevax-stock-nosedives-on-monday---heres-why

Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroen...

 hillevax-shares-resume-trade
HilleVax Shares Resume Trade
07/08/2024 13:41:38

 hillevaxs-phase-2b-nest-in1-study-of-norovirus-vaccine-fails-to-meet-primary-endpoint

HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION